Navigation Links
Cerevast Therapeutics Receives CE Mark for Clotbust ER™ Ultrasound Stroke Treatment Device
Date:12/19/2011

REDMOND, Wash., Dec. 19, 2011 /PRNewswire/ -- Cerevast Therapeutics Inc., a privately held medical technology company, announced today that it has received CE mark clearance of its SonoLysis Headframe System, the Clotbust ER™ providing approval to commercialize the product in Europe.

(Logo: http://photos.prnewswire.com/prnh/20111219/SF24705LOGO)

The Clotbust ER™ is a first-in-class ultrasound device for the treatment of ischemic stroke, representing a novel product in an extremely high area of unmet medical need. Designed for rapid deployment in the emergency room setting, the device has been engineered to non-invasively deliver therapeutic ultrasound energy to the region of the occluded vessel in the brain as a treatment for ischemic stroke when used in combination with standard intravenous thrombolytic therapy (tissue plasminogen activator - tPA/Alteplase).

The device contains multiple transducers incorporated into a unique, operator-independent headframe.  The Clotbust ER™ is designed to self-align the transducers based on common landmarks on the skull.  Proprietary software controls the ultrasound parameters, which in turn allows the device to deliver consistent therapeutic levels of ultrasound energy necessary to achieve acoustic streaming and enhanced clot lysis within the occluded vessel of the brain without the need for a trained sonographer or vascular technician.

"Achieving CE mark clearance represents a major accomplishment for Cerevast," said Bradford A. Zakes, Chief Executive Officer. "The Clotbust ER™ significantly reduces the technical challenges associated with the administration of transcranial ultrasound for the treatment of ischemic stroke.  Unlike conventional Doppler instruments that are designed and approved for diagnostic purposes only, the Clot
'/>"/>

SOURCE Cerevast Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015  Healthcare reform ... of many new forms of provider networks, such ... Organizations (ACOs). The rapid evolution of these networks ... their access, pricing and service delivery systems to ... To help the pharma sector adapt to ...
(Date:4/17/2015)... 2015 Research and Markets ( ... "Medical Device Outsourcing - Global Strategic Business ... This report analyzes the worldwide markets for Medical ... Device Categories: Class I, Class II, and Class ... report Include - Radiology, Orthopedic, Neurology, Cardiology, and ...
(Date:4/17/2015)... 17, 2015  Trovagene, Inc., (NASDAQ:  TROV) a ... clinical data presented at the 2015 European Lung ... Cancer Monitoring ℠ (PCM) platform outperformed tissue ... EGFR T790M mutations in metastatic lung cancer ... T790M Mutation in Urinary Circulating Tumor DNA from ...
Breaking Medicine Technology:Pharmaceutical Industry Struggling to Better Serve Provider Networks Such as Accountable Care Organizations (ACOs) 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4
... BETHESDA, Md., April 14 Micromet, Inc.,(Nasdaq: ... novel, proprietary,antibodies for the treatment of cancer, ... meeting of the American Association for,Cancer Research ... that commercial,anti-cancer antibodies trastuzumab (Herceptin(R); Genentech, Roche),cetuximab ...
... the, Tumor Suppressor P53 Inhibited Tumor Growth Synergistically in Preclinical ... ... 14 ,Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) announced today that ... 2008 Annual Meeting of the American Association for Cancer Research,(AACR) further ...
Cached Medicine Technology:Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 2Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 3Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 4Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 5Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 2Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 3Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 4
(Date:4/18/2015)... Compare-autoinsurance.org has released a new blog ... insurance policy . , Clients should no longer ... online is safe and reliable. An insurance brokerage website ... displayed on a single web page, so drivers do ... is now possible to compare online car insurance quotes ...
(Date:4/18/2015)... April 18, 2015 "I wanted ... to create a healthful juice that contained essential ... Rosedale, Md. "It increases my energy, improves skin ... , He developed Tapp's Juice to contain fruits, ... to prevent physical and mental fatigue. It features ...
(Date:4/18/2015)... Patients who undergo radiation for a hematologic cancer ... but the disease is likely to differ in some ... Surviving Mesothelioma has just posted the details of this ... read it now. , Scientists from China, the ... who had both a hematologic cancer (like lymphoma or ...
(Date:4/18/2015)... 18, 2015 Aureus Medical Group ... including physical therapy jobs, has announced that it ... Carolina Physical Therapy Association Annual Conference to be ... in Greenville, SC. , The SCAPTA Annual ... with products and services. , Representatives from ...
(Date:4/17/2015)... John Evans, a Gardant affordable assisted ... from 2 p.m. to 3 p.m. on April 24. ... Ct. in Pekin, Illinois, serves older adults of all ... to maintain their independence. , Becky Baker will entertain ... be served during the luau. , For more information, ...
Breaking Medicine News(10 mins):Health News:A Guide For Avoiding Online Auto Insurance Scams! 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2
... July 8 Governor Edward G.,Rendell today issued ... Containment Council (PHC4), which closed after the law,authorizing ... Governor acted similarly in 2003, when PHC4 was ... later reauthorized by legislative action., The Rendell ...
... Study Validates Use of Pharos Innovation,s Proprietary,Device-Free Remote Monitoring Platform ... ... Medical Costs, NORTHFIELD, Ill., July 8 ... generation clinical and financial,performance improvement through a device-free remote monitoring ...
... Barbara Ann Karmanos,Cancer Center announced that it has ... lease space and equipment at the Meadowbrook Medical,Center, ... foot,space will allow Karmanos to expand its outreach ... as well as provide access to radiation,oncology, medical ...
... single nucleotide polymorphisms (SNPs), that are associated with a ... breast cancer do not appear to substantially improve the ... predict an individual,s risk, according to a study in ... of the National Cancer Institute . , Risk prediction ...
... PITTSBURGHUniversity of Pittsburgh-led researchers could provide new insight ... deformity and arteriovenous malformations (AVMs)develop in humans, as ... Developmental Biology . , Led by Beth Roman, ... School of Arts and Sciences, the team created ...
... yet to show drop-off in access predicted by critics ... have not lost access to care despite federal legislation ... years, a new report finds. , Critics feared the ... make treatment more difficult, but investigators from the Duke ...
Cached Medicine News:Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 2Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 3Health News:Iowa Medicaid Demonstration Finds Tel-Assurance(R) Remote Monitoring Platform Improved Health Status and Saved $5 Million 2Health News:Iowa Medicaid Demonstration Finds Tel-Assurance(R) Remote Monitoring Platform Improved Health Status and Saved $5 Million 3Health News:Karmanos Cancer Center Partners With Meadowbrook to Expand Outreach and Access for Cancer Services 2Health News:Single-nucleotide polymorphisms do not substantially improve risk prediction for breast cancer 2Health News:Pitt-led research provides insight into development of congenital circulatory defects 2Health News:Cancer Care Unaffected by Doctor Reimbursement Changes 2
The rotating stage assembly is designed to give the researcher maximum flexibility in the mounting of specimens. It can be turned to any horizontal and vertical angle via a ball joint mounting arran...
Punch set for Advanced Tissue Arrayer, 2.0 mm...
Inquire...
Inquire...
Medicine Products: